Zucara Therapeutics scores Series A

Toronto-based Zucara Therapeutics, a diabetes life sciences company, has raised US$21 million in Series A financing.

31 March 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles